Reactive and Inactive Skin Decontamination Lotion

This is a Sources Sought Notice only. This is not a Request for Proposal, Request for Quote, or Invitation for Bid. DLA Troop Support is seeking to identify possible sources that can manufacture the following: Reactive Skin Decontamination Lotion (RSDL), NSN 6505-01-507-5074 Inactive Skin Decontamination Lotion (ISDL), NSN 6910-01-507-5141. RSDL shall be a topical lotion containing a free oxime dissolved in a maximum of polyethylene glycol monomethyl ether and water. It is intended to remove or neutralize chemical warfare (CW) agents, including many organophosphate-based pesticides and T-2 toxin from the skin. Shall be pre-impregnated in a suitable sponge applicator pad. Each applicator pad shall be individually packaged in a heat sealed polyethylene-lined aluminum foil pouch. The foil pouch shall permit easy opening of the package when wearing CW protective clothing. Shall be cleared for use by the United States (U.S.) Food and Drug Administration (FDA) for application on unbroken skin of hands, face, neck, limbs and torso. ISDL is a training lotion that imitates the properties of the decontamination lotion in all but active decontaminating ingredients. DLA Troop Support is in the process of developing a solicitation for the referenced item. The annual estimated required quantity is 11,098 packages (PG) Reactive Skin Decontamination Lotion (RSDL), 1,364 packages (PG) Inactive Skin Decontamination Lotion (ISDL).. Ordered quantities shall be delivered to military ordering activities. Delivery shall occur 75 days after receipt of the order. If your firm can provide these items, please provide information with respects to the following: 1. Place of Manufacture 2. Estimated Annual Capacity 3. FDA registration information 4. Product Name and description including description of any special features 5. Current unit sale price 6. Estimated inventory level and storage requirements 7. Delivery days for each item *** New Products Under Development *** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture lotions described in this Request For Information (RFI) or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protect Critical infrastructure information (PCII) Program outlined in the Critical Infrastructure Information Act 2002. Your Response to this RFI may be submitted electronically in pdf format and emailed to the Contract Specialist Myrna.Rodriguez@dla.mil before April 12, 2021.